{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:33:43Z","timestamp":1787027623657,"version":"build-2736575974"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Cystic fibrosis (CF) is a multisystem genetic disorder in which malnutrition has historically been a major determinant of disease severity. The advent of CFTR modulators has significantly altered the nutritional and functional profile of CF patients. This systematic review, conducted following PRISMA guidelines and registered on PROSPERO, summarizes studies published from 2012 to 2025 that evaluated the impact of CFTR modulators on nutritional status, body composition, and respiratory function, with a particular focus on the relationship between BMI changes and FEV1. Seventeen studies including both pediatric and adult populations were identified and analyzed. All studies reported significant increases in BMI following modulator therapy, ranging from +0.9 to +1.6 kg\/m2 after 6\u201312 months of elexacaftor\/tezacaftor\/ivacaftor (ETI), accompanied by improvements in FEV1 of 7\u201313 percentage points. Weight gain was primarily due to increases in fat mass (60\u201375%). Improvements in albumin, prealbumin, and vitamin levels, along with reductions in C-reactive protein (CRP) and fecal calprotectin, reflected systemic metabolic recovery. However, a marked increase in overweight and obesity (up to 40%), together with increased visceral adiposity, has also been observed. Overall, CFTR modulators result in significant nutritional and functional improvements, highlighting the need for strategies that prioritize overall metabolic health rather than weight gain alone.<\/jats:p>","DOI":"10.3390\/biology15040367","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:00:52Z","timestamp":1771840852000},"page":"367","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-1790","authenticated-orcid":false,"given":"Giovanna","family":"Linguiti","sequence":"first","affiliation":[{"name":"Pediatric Unit \u201cB. Trambusti\u201d, Cystic Fibrosis Regional Reference Center, Department of Interdisciplinary Medicine, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Granberg","sequence":"additional","affiliation":[{"name":"Pediatric Unit \u201cB. Trambusti\u201d, Cystic Fibrosis Regional Reference Center, Department of Interdisciplinary Medicine, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Leonetti","sequence":"additional","affiliation":[{"name":"Pediatric Unit \u201cB. Trambusti\u201d, Cystic Fibrosis Regional Reference Center, Department of Interdisciplinary Medicine, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lassandro","sequence":"additional","affiliation":[{"name":"Pediatric Unit \u201cB. Trambusti\u201d, Cystic Fibrosis Regional Reference Center, Department of Interdisciplinary Medicine, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Lassandro","sequence":"additional","affiliation":[{"name":"Pediatric Unit \u201cB. Trambusti\u201d, Cystic Fibrosis Regional Reference Center, Department of Interdisciplinary Medicine, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1528-0012","authenticated-orcid":false,"given":"Maurizio","family":"Delvecchio","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Giordano","sequence":"additional","affiliation":[{"name":"Pediatric Unit \u201cB. Trambusti\u201d, Cystic Fibrosis Regional Reference Center, Department of Interdisciplinary Medicine, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Giordano, P., Linguiti, G., Leonetti, G., Casolino, R.M.P., Granberg, V., and Faienza, M.F. (2025). Bone Disease in Cystic Fibrosis: Insights into Etiopathogenesis and Advances in Treatment Management. J. Clin. Med., 14.","DOI":"10.3390\/jcm14165657"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcf.2021.05.002","article-title":"Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study","volume":"21","author":"Gramegna","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10620-015-3834-2","article-title":"Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor","volume":"61","author":"Borowitz","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Giordano, P., Leonetti, G., Granberg, V., Casolino, R.M.P., Lassandro, G., Delvecchio, M., and Linguiti, G. (2025). Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic fibrosis-related diabetes: A systematic review. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1623654"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcf.2023.04.019","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis","volume":"22","author":"Schembri","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111124","DOI":"10.1016\/j.nut.2020.111124","article-title":"Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension","volume":"85","author":"King","year":"2021","journal-title":"Nutrition"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jcf.2023.04.010","article-title":"Changes in nutrition and growth status in young children in the first 12 weeks of ivacaftor therapy","volume":"22","author":"Tindall","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/s41598-025-86010-1","article-title":"Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data","volume":"15","author":"Imrei","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clnesp.2023.08.028","article-title":"Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis","volume":"58","author":"Taelman","year":"2023","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","article-title":"A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation","volume":"42","author":"Marazuela","year":"2023","journal-title":"Clin. Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hevilla, F., Porras, N., Gir\u00f3n, M.V., Garc\u00eda-Olivares, M., Padial, M., S\u00e1nchez-Torralvo, F.J., Olveira, C., and Olveira, G. (2024). Impact of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study. Nutrients, 16.","DOI":"10.3390\/nu16193293"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sol\u00eds-Garc\u00eda, M., Garc\u00eda-Clemente, M.M., Madrid-Carbajal, C.J., Pel\u00e1ez, A., G\u00f3mez Punter, R.M., Eiros Bachiller, J.M., and Moreno, R.M.G. (2024). Is Obesity a Problem in New Cystic Fibrosis Treatments?. Nutrients, 16.","DOI":"10.3390\/nu16183103"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/tezacaftor\/ivacaftor influences body composition in adults with cystic fibrosis: A fully automated CT-based analysis","volume":"14","author":"Haubold","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112425","DOI":"10.1016\/j.nut.2024.112425","article-title":"Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: A follow-up study","volume":"123","author":"Marazuela","year":"2024","journal-title":"Nutrition"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clnu.2025.04.027","article-title":"Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"50","author":"Enaud","year":"2025","journal-title":"Clin. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.clnesp.2025.04.006","article-title":"Assessment of dietary intake in adults with cystic fibrosis pre and post commencement of Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"67","author":"Loel","year":"2025","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e71044","DOI":"10.1002\/ppul.71044","article-title":"Peripheral Muscle Function and Body Composition in People with Cystic Fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor: A Cross-Sectional Single-Centre Study","volume":"60","author":"Clayton","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_21","first-page":"100272","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ncp.10251","article-title":"Association between fat-free mass and pulmonary function in patients with cystic fibrosis: A narrative review","volume":"34","author":"Gomes","year":"2019","journal-title":"Nutr. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nut.2017.10.026","article-title":"Association between body composition and pulmonary function in children and young people with cystic fibrosis","volume":"48","author":"Calella","year":"2018","journal-title":"Nutrition"},{"key":"ref_24","first-page":"376","article-title":"Assessment of body composition in cystic fibrosis: Agreement between skinfold measurement and densitometry","volume":"39","author":"Olveira","year":"2022","journal-title":"Nutr. Hosp."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.clnu.2012.04.012","article-title":"Use of body mass index percentile to identify fat-free mass depletion in children with cystic fibrosis","volume":"31","author":"Engelen","year":"2012","journal-title":"Clin. Nutr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.rmed.2018.07.016","article-title":"Nutritional status and pulmonary outcome in children and young people with cystic fibrosis","volume":"142","author":"Papalexopoulou","year":"2018","journal-title":"Respir. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Scully, K.J., Jay, L.T., Freedman, S., Sawicki, G.S., Uluer, A., Finkelstein, J.S., and Putman, M.S. (2022). The relationship between body composition, dietary intake, physical activity, and pulmonary status in adolescents and adults with cystic fibrosis. Nutrients, 14.","DOI":"10.3390\/nu14020310"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcf.2016.11.005","article-title":"BMI fails to identify poor nutritional status in stunted children with CF","volume":"16","author":"Konstan","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ncp.11332","article-title":"Evolving nutrition therapy in cystic fibrosis: Adapting to the CFTR modulator era","volume":"40","author":"Sankararaman","year":"2025","journal-title":"Nutr. Clin. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Khemka, S., Hunter, S., Jones, J., Valent\u00edn-Mart\u00ednez, K., Chadwick, C.C., and Bass, R. (2025). The state of weight in cystic fibrosis: Understanding nutritional status and individualizing nutritional care in the modulator era. Nutrients, 17.","DOI":"10.3390\/nu17152533"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of CFTR mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8382","DOI":"10.1038\/ncomms9382","article-title":"Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis","volume":"6","author":"Corvol","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: Consensus guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sheikh, S., Zemel, B.S., Stallings, V.A., Rubenstein, R.C., and Kelly, A. (2014). Body composition and pulmonary function in cystic fibrosis. Front. Pediatr., 2.","DOI":"10.3389\/fped.2014.00033"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e70083","DOI":"10.1002\/prp2.70083","article-title":"Improved Clinical Outcomes with Elexacaftor\/Tezacaftor\/Ivacaftor in Patients with Cystic Fibrosis and Advanced Lung Disease: Real-World Evidence from an Italian Single-Center Study","volume":"13","author":"Perrotta","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2307\/2389364","article-title":"Trade-offs in life-history evolution","volume":"3","author":"Stearns","year":"1989","journal-title":"Funct. Ecol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Rauw, W.M. (2012). Immune response from a resource allocation perspective. Front. Genet., 3.","DOI":"10.3389\/fgene.2012.00267"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/1749-4877.12889","article-title":"Mounting an immune response reduces male attractiveness in a lizard","volume":"20","author":"Comas","year":"2025","journal-title":"Integr. Zool."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor\/Tezacaftor\/Ivacaftor: PROMISE-ENDO","volume":"110","author":"Chan","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/4\/367\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:23:29Z","timestamp":1771842209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/4\/367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["biology15040367"],"URL":"https:\/\/doi.org\/10.3390\/biology15040367","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]}}}